CJC-1295 - With DAC 2mg

Description

CJC-1295 With DAC Technical Overview

CJC-1295 with Drug Affinity Complex (DAC) is a synthetic long-acting analogue of growth hormone-releasing hormone.

Its chemical modifications include an albumin-associated component designed to prolong systemic exposure in experimental pharmacology.

Published clinical research has examined changes in growth hormone and IGF-1 after exposure to the DAC-modified peptide.

Compound Specifications

Storage and Handling

• Follow manufacturer-specified stability requirements.
• Protect from moisture and contamination.
• Use appropriate laboratory handling methods.

Lyophilized Format

CJC-1295 With DAC may be manufactured in lyophilized form. Stability depends on chemical structure and formulation.

Research Use Disclaimer

CJC-1295 is not FDA-approved for human therapeutic use. For laboratory research only.

Frequently Asked Questions

What Is CJC-1295 With DAC?

A modified GHRH analogue containing a Drug Affinity Complex.

What Is DAC?

A chemical modification associated with albumin binding.

Which Receptor Is Involved?

GHRHR.

Is This the Same as CJC-1295 Without DAC?

No. The chemical modifications differ.

Research Overview

CJC-1295 has been studied as a long-acting GHRH analogue.

GHRHR Activation

Research investigates receptor-mediated signaling.

Albumin Association

The DAC group supports protein association.

GH and IGF-1 Research

Clinical pharmacology studies have investigated endocrine responses.

Research Applications

References

1. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295. View publication.

Certificate of Analysis (COA)

Documentation should verify the DAC-modified chemical structure, purity, and content.

Peptide Lives